Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

certolizumab pegol

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

- PMLiVE

NICE’s long-serving chief exec Sir Andrew Dillon to step down

Pharma leader praises "laser focus" on thorny access questions

- PMLiVE

NICE’s fast-track catapults Skyrizi into market

Watchdog also gives direction on comparing rival treatments

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

- PMLiVE

NICE unveils long-awaited review of methodologies

Use of quality of life measures to be reviewed

- PMLiVE

Kisqali combination follows Verzenio onto Cancer Drugs Fund

Drug must prove its value via managed access route

- PMLiVE

AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

New fast-track appraisal a boon for companies

- PMLiVE

UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D

Pilot much more to industry liking, but devil will be in detail

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

- PMLiVE

AbbVie’s upadacitinib tops Humira again in arthritis trial

Firm says pipeline drug only JAK inhibitor to show superiority

- PMLiVE

Akcea steals march on Alnylam with NICE approval

Advantage to Tegsedi over Onpattro

- PMLiVE

NICE says no to Novartis’ Kisqali combo in breast cancer

Double blow after Lilly rival recommended

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links